2020-07-17 |
1 |
Complaint |
succeeded in obtaining a patent—U.S. Patent No.
9,220,631 (the “’631 Patent”)—broadly claiming a PFS …of the ’631 Patent) showing that the claimed PFS in Novartis’s patent was not
patentable. Separately,…the patentability of
claims of the ’631 Patent. As detailed below, the claims of the ’631 Patent would…material to the patentability of the claims of the ’631 Patent
because the ’631 Patent would not have …PFS, Novartis could secure its patent only by ensuring that the U.S. Patent and Trademark Office
(“USPTO |
External link to document |
2021-03-01 |
103 |
Protective Order |
(a) “’631 Patent” refers to United States Patent No. 9,220,631.
(b) …foreign patents or patent applications, or any other domestic or foreign
patent or patent application… or foreign patent or patent
application claiming priority to the ’631 Patent or any related… or foreign patent or patent application claiming priority to the ’631
Patent or any related…modifying of patent claims or participation in domestic and/or
foreign patent office correspondence |
External link to document |
2021-04-12 |
112 |
Exhibit A - ITC Staff Brief |
of certain claims of U.S.
Patent No. 9,220,631 (JX-0001) (“the ’631 patent”) based on the importation….................... 21
IV. U.S. PATENT NO. 9,220,631 ........................................… Public Version
IV. U.S. PATENT NO. 9,220,631
A. Claim Construction
…syringe. (Id.)
D. The ’631 Patent
The ’631 patent is titled “SYRINGE” and issued on December…, selling, or importing a patented invention without consent of the
patent owner. 35 U.S.C. § 271(a). |
External link to document |
2021-09-21 |
139 |
Memorandum & Opinion |
of the underlying patent application
for U.S. Patent No. 9,220,631 (the ‘631 Patent). Id. ¶¶ 8, 256. …the ‘631 Patent “through fraud on the USPTO.” Id.
Regeneron alleges that the ‘631 Patent dramatically…Novartis’s patent infringement suit. As outlined above, the
enforceability of the ‘631 Patent runs throughout…. The ‘631 Patent “broadly
claim[s] a PFS with any anti-VEGF, including EYELEA.” Id. ¶ 8. According to… to Regeneron, the
‘631 Patent is at “the heart of Defendants’ anticompetitive conduct” and a “cornerstone |
External link to document |
2020-12-21 |
76 |
Protective Order |
(a) “’631 Patent” refers to United States Patent No. 9,220,631.
(b) …foreign patents or patent applications, or any other domestic or foreign
patent or patent application…domestic or foreign patent or patent
application claiming priority to the ’631 Patent or any related…domestic or foreign patent or patent application claiming priority to the ’631
Patent or any related…modifying of patent claims or participation in domestic and/or
foreign patent office correspondence |
External link to document |
2021-01-24 |
87 |
Amended Complaint |
succeeded in obtaining a patent—U.S. Patent No.
9,220,631 (the “’631 Patent”)—broadly claiming a PFS …of the ’631 Patent) showing that the claimed PFS in Novartis’s patent was not
patentable. And unbeknownst…the
patentability of claims of the ’631 Patent. As detailed below, the claims of the ’631 Patent would…material to the patentability of the claims of the ’631 Patent
because the ’631 Patent would not have …of the ’631 Patent, which is itself unlawful under the patent laws and
renders the patent invalid.
|
External link to document |